



Dkt. No. INT 004.10  
USSN 10/004,118  
PATENT

**CERTIFICATE OF FIRST CLASS MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service under 37 CFR §1.8 on the date indicated below and with sufficient postage addressed to Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

Gary R. Fabian

Printed Name

Signature

*Gary R. Fabian*

*28 April 2009*

Date of Deposit

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Application of: MORAN, Stanford  
Mark

Confirmation No.: 8022

Serial No.: 10/004,118

Art Unit: 1647

Filing Date: 30 October 2001

Examiner: Seharaseyon, J.

Title: METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON

**TRANSMITTAL**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing in the above-referenced application are the following documents:

1. Transmittal;
2. Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97;
3. Modified Form 1449 and copies of twenty-one cited non-US Patent publication references;
4. Certificates of First Class Mailing;
5. Return Receipt Postcard.

**Authorization to Charge Deposit Account:**

The Commissioner is hereby authorized to charge \$180.00 under 1.17(p) for Submission of an Information Disclosure Statement to Deposit Account No. 504212 (please reference docket

number INT 004.10). No additional fees are believed due in connection with this paper. However, the Commissioner is hereby authorized to charge to Deposit Account No. 504212 (please reference docket number INT 004.10) any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, with the exception of the payment of the Issue Fee.

Address all future communications to:

**Customer Number: 000074866**

Barbara G. McClung, Esq.  
Registration No. 33,113  
Vice President, General Counsel and Corporate Secretary  
Intarcia Therapeutics, Inc.  
24650 Industrial Blvd.  
Hayward, CA 94545  
Phone: 510-782-7800 ext. 122  
Facsimile: 510-782-7801.

Respectfully submitted,

Date: 28 April 2009 By: Gary R. Fabian  
Gary R. Fabian, Ph.D.  
Registration No. 33,875  
Agent for Applicant



Dkt. No. INT 004.10  
USSN 10/004,118  
PATENT

**CERTIFICATE OF FIRST CLASS MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service under 37 CFR §1.8 on the date indicated below and with sufficient postage addressed to Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

Printed Name Gary R. Fabian  
Signature *Gary R. Fabian*  
Date of Deposit 28 Apr. 12009

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Application of: MORAN, Stanford Mark	Confirmation No.: 8022
Serial No.: 10/004,118	Art Unit: 1647
Filing Date: 30 October 2001	Examiner: Seharaseyon, J.
Title: METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON	

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. § 1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

03/01/2009 LUGUYEN1 00000026 504212 10004118  
01 FC:1006 100.00 DA

Sir:

The information listed below may be material to the examination of the above-identified application. A completed Form PTO-1449 and copies of the cited references accompany this paper. Copies of cited U.S. Patent and U.S. Patent Application publications have not been submitted (37 C.F.R. §1.98(a)(2)(ii)).

Please note that WO 99/62501 corresponds to U.S. Patent No. 7,101,567.

Applicant requests that the Examiner initial and return the form to indicate that the references have been reviewed and made of record in the present application.

This Supplemental Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

**Authorization to Charge Deposit Account:**

No additional fees are believed due in connection with this paper. However, the Commissioner is hereby authorized to charge to Deposit Account No. **504212** (please reference docket number **INT 004.10**) any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, with the exception of the payment of the Issue Fee.

Address all future communications to **Customer Number: 000074866**

Barbara G. McClung, Esq.  
Vice President, General Counsel and Corporate Secretary  
Intarcia Therapeutics, Inc.  
24650 Industrial Blvd.  
Hayward, CA 94545  
Phone: 510-782-7800 ext. 122  
Facsimile: 510-782-7801.

Respectfully submitted,

Date:

28 April 2009

By:

Gary R. Fabian

Gary R. Fabian, Ph.D.  
Registration No. 33,875  
Agent for Applicant